

Frédéric Pouliot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5578678/publications.pdf>

Version: 2024-02-01

56
papers

5,080
citations

361413

20
h-index

161849

54
g-index

56
all docs

56
docs citations

56
times ranked

7192
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	27.0	2,319
2	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 1563-1573.	10.7	466
3	Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. <i>Anaesthesia</i> , 2021, 76, 748-758.	3.8	365
4	Positive Surgical Margin Appears to Have Negligible Impact on Survival of Renal Cell Carcinomas Treated by Nephron-Sparing Surgery. <i>European Urology</i> , 2010, 57, 466-473.	1.9	225
5	Exosomes Induce Fibroblast Differentiation into Cancer-Associated Fibroblasts through TGF β 2 Signaling. <i>Molecular Cancer Research</i> , 2018, 16, 1196-1204.	3.4	200
6	Cancer-associated fibroblasts induce epithelial-mesenchymal transition of bladder cancer cells through paracrine IL-6 signalling. <i>BMC Cancer</i> , 2019, 19, 137.	2.6	190
7	A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ¹⁸ F-DCFPyL in Prostate Cancer Patients (OSPREY). <i>Journal of Urology</i> , 2021, 206, 52-61.	0.4	180
8	Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. <i>Clinical Cancer Research</i> , 2021, 27, 3674-3682.	7.0	179
9	CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy. <i>Cancer Research</i> , 2015, 75, 950-962.	0.9	150
10	Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. <i>Cancer Research</i> , 2003, 63, 277-81.	0.9	69
11	Prospective, Multisite, International Comparison of ¹⁸ F-Fluoromethylcholine PET/CT, Multiparametric MRI, and ⁶⁸ Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. <i>Journal of Nuclear Medicine</i> , 2019, 60, 794-800.	5.0	61
12	Is Routine Renal Tumor Biopsy Associated with Lower Rates of Benign Histology following Nephrectomy for Small Renal Masses?. <i>Journal of Urology</i> , 2018, 200, 731-736.	0.4	60
13	Basic Research in Kidney Cancer. <i>European Urology</i> , 2011, 60, 622-633.	1.9	55
14	Regulation of the Human Cyclin-dependent Kinase Inhibitor p18 by the Transcription Factors E2F1 and Sp1. <i>Journal of Biological Chemistry</i> , 2002, 277, 31679-31693.	3.4	54
15	FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. <i>Cancer Imaging</i> , 2015, 15, 2.	2.8	47
16	Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery. <i>Biomaterials</i> , 2017, 145, 233-241.	11.4	47
17	PSMA Theranostics: Current Landscape and Future Outlook. <i>Cancers</i> , 2021, 13, 4023.	3.7	33
18	CUA guideline on the management of cystic renal lesions. <i>Canadian Urological Association Journal</i> , 2017, 11, 66.	0.6	30

#	ARTICLE	IF	CITATIONS
19	Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration. <i>European Urology Focus</i> , 2019, 5, 998-1006.	3.1	25
20	Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, 317-321.	1.4	21
21	A Canadian framework for managing prostate cancer during the COVID-19 pandemic: Recommendations from the Canadian Urologic Oncology Group and the Canadian Urological Association. <i>Canadian Urological Association Journal</i> , 2020, 14, 163-168.	0.6	20
22	Outcomes of complete metastasectomy in metastatic renal cell carcinoma patients: The Canadian Kidney Cancer information system experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 799.e1-799.e10.	1.6	18
23	Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naïve and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 14, 17-23.	0.6	17
24	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. <i>Canadian Urological Association Journal</i> , 2018, 12, 173-80.	0.6	16
25	Metabolic Imaging of Prostate Cancer Reveals Inpatient Intermetastasis Response Heterogeneity to Systemic Therapy. <i>European Urology Focus</i> , 2017, 3, 639-642.	3.1	15
26	Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study. <i>European Urology Oncology</i> , 2020, 3, 298-305.	5.4	15
27	Modeling human bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1759-1766.	2.2	14
28	Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2018, 12, 231-238.	0.6	14
29	Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial. <i>Clinical Cancer Research</i> , 2018, 24, 5305-5312.	7.0	13
30	Determining Generalizability of the Canadian Kidney Cancer information system (CKCis) to the Entire Canadian Kidney Cancer Population. <i>Canadian Urological Association Journal</i> , 2020, 14, E499-E506.	0.6	13
31	Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction. <i>Cancer Prevention Research</i> , 2016, 9, 189-195.	1.5	11
32	Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 359-365.	1.3	11
33	A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine. <i>Canadian Urological Association Journal</i> , 2020, 14, 319-321.	0.6	11
34	Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2021, 205, 78-85.	0.4	11
35	Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100064.	3.8	11
36	Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation. <i>Drug Metabolism and Disposition</i> , 2020, 48, 75-84.	3.3	10

#	ARTICLE	IF	CITATIONS
37	Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 836.e19-836.e27.	1.6	9
38	Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective. <i>Canadian Urological Association Journal</i> , 2017, 11, 232-7.	0.6	8
39	Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 521-530.	1.9	8
40	Extragenital Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. <i>Journal of Urology</i> , 2020, 203, 940-948.	0.4	8
41	Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians. <i>Canadian Urological Association Journal</i> , 2017, 11, 204.	0.6	7
42	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of renal mass biopsy in the management of kidney cancer. <i>Canadian Urological Association Journal</i> , 2019, 13, 377-383.	0.6	6
43	Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4516-4516.	1.6	6
44	Discordance between testosterone measurement methods in castrated prostate cancer patients. <i>Endocrine Connections</i> , 2019, 8, 132-140.	1.9	6
45	Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial. <i>Journal of Urology</i> , 2021, 205, 1303-1309.	0.4	5
46	Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 1166-1176.	0.4	5
47	Renal hypothermia during partial nephrectomy for patients with renal tumours: a randomised controlled clinical trial protocol. <i>BMJ Open</i> , 2019, 9, e025662.	1.9	4
48	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 576.e11-576.e16.	1.6	3
49	Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence. <i>Canadian Urological Association Journal</i> , 2018, 12, E415-20.	0.6	2
50	Ultrasound Correlates Highly With Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort. <i>Urology</i> , 2022, , .	1.0	2
51	A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers: Results from the Canadian Kidney Cancer Information System. <i>Journal of Urology</i> , 2022, 208, 804-812.	0.4	2
52	Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. <i>Canadian Urological Association Journal</i> , 2020, 15, 132-137.	0.6	1
53	Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort. <i>Urology</i> , 2021, , .	1.0	1
54	Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. <i>Clinical Genitourinary Cancer</i> , 2022, , .	1.9	1

#	ARTICLE	IF	CITATIONS
55	Reply By Authors. Journal of Urology, 2021, 205, 84-85.	0.4	0
56	Reply by Authors. Journal of Urology, 2021, 206, 1176.	0.4	0